Gilead Sciences and Yale School of Medicine in Potential US$100 M Cancer Research Pact

2011 ◽  
Vol 2011 (4) ◽  
Author(s):  
Heather Cartwright
Author(s):  
Cheryl Y Yip

Dr. John Di Guglielmo was born and raised in Montreal, where he completed his BSc and PhD degrees in Biochemistry at McGill University. During this time, he discovered and grew his passion for conducting basic cancer research. After his post doctorate fellowship at the Samuel Lunenfeld Research Institute (Mount Sinai Hospital, Toronto, ON), Dr. Di Guglielmo came to Western University as an Assistant Professor. Today, he is an Associate Professor in the Physiology and Pharmacology department at Western’s Schulich School of Medicine and Dentistry. Cheryl Yip, an Academic Affairs Coordinator for WURJHNS, had the opportunity to interview Dr. Di Guglielmo to learn more about his career in research.


2013 ◽  
Vol 17 (12) ◽  
pp. 74-81

Nuvilex acquires rights to use Austrianova's technology. Cancer Research Technology and Nuevolution collaborate to seek potential cancer drugs. JPT and Immudex enter partnership. BIOQuebec and Rx&D join forces to strengthen Canada's biotechnology sector. Helsinn and Chugai Pharma Marketing enter into agreement. Berg and Icahn School of Medicine at Mount Sinai announce R&D partnership for drug discovery and development. NovAliX and Kyowa Hakko Kirin to collaborate on Fragment-Based Drug Discovery Project. Biopharm GmbH enters into co-research agreement with Merck. Agilent Technologies to collaborate with University of Queensland on oral cancer research. PSR-Agility Orphan Drug Development wins ROAR Award for “Best Orphan Drug CRO”. Vietnam Ministry of Health and Quintiles collaborate to advance clinical trial excellence. Morflora's TraitUP™ wins Agrow Awards for the Best Novel Agricultural Biotechnology. Europe's most influential Biomarkers Congress. Manchester, to be held in UK February 2014.


Sign in / Sign up

Export Citation Format

Share Document